Melanoma
September 2020 Vol 11, No 9 | September 9, 2020
A single infusion of autologous cryopreserved tumor-infiltrating lymphocyte (TIL) therapy (lifileucel) induced responses in more than one-third of patients with advanced melanoma who had disease progression on multiple prior therapies, including anti–PD-1 and BRAF/MEK inhibitors, according to an update of a phase 2 global multicohort study.
July 2020 Vol 11, No 7 | July 9, 2020
The combination of the checkpoint
inhibitor atezolizumab plus the
BRAF inhibitor vemurafenib and
the MEK inhibitor cobimetinib improved
progression-free survival (PFS) and lengthened
duration of responses compared with
the 2 targeted therapies plus placebo in
newly diagnosed BRAF V600E/K–mutant
advanced melanoma, according to results
of the phase 3 IMspire150 trial presented
at the 2020 virtual meeting of the American
Association for Cancer Research.
October 2019 Vol 10, No 10 | October 2, 2019
Moving combination immunotherapy into the neoadjuvant setting for patients with stage III melanoma induces a higher rate of pathologic response than adjuvant therapy, said Christian U. Blank, MD, PhD, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Results 1 - 3 of 3
